{"name":"China National Center for Cardiovascular Diseases","slug":"china-national-center-for-cardiovascular-diseases","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Aspirin + Clopidogrel + Rivaroxaban","genericName":"Aspirin + Clopidogrel + Rivaroxaban","slug":"aspirin-clopidogrel-rivaroxaban","indication":"Acute coronary syndrome with high thrombotic risk","status":"marketed"},{"name":"De-escalated Dual Antiplatelet Therapy","genericName":"De-escalated Dual Antiplatelet Therapy","slug":"de-escalated-dual-antiplatelet-therapy","indication":"Acute coronary syndrome with percutaneous coronary intervention","status":"marketed"},{"name":"Intensive BP treatment group","genericName":"Intensive BP treatment group","slug":"intensive-bp-treatment-group","indication":"Hypertension with cardiovascular disease or high cardiovascular risk","status":"phase_3"},{"name":"Oral anticoagulation therapy","genericName":"Oral anticoagulation therapy","slug":"oral-anticoagulation-therapy","indication":"Atrial fibrillation for stroke prevention","status":"marketed"},{"name":"Single antiplatelet therapy","genericName":"Single antiplatelet therapy","slug":"single-antiplatelet-therapy","indication":"Cardiovascular disease prevention","status":"marketed"},{"name":"Torsemide Tablets","genericName":"Torsemide Tablets","slug":"torsemide-tablets","indication":"Edema associated with congestive heart failure","status":"marketed"},{"name":"low-dose rivaroxaban","genericName":"low-dose rivaroxaban","slug":"low-dose-rivaroxaban","indication":"Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Berberine plus lifestyle intervention","genericName":"Berberine plus lifestyle intervention","slug":"berberine-plus-lifestyle-intervention","indication":"Other","status":"marketed"},{"name":"Qishen Yiqi Drop Pills","genericName":"Qishen Yiqi Drop Pills","slug":"qishen-yiqi-drop-pills","indication":"Other","status":"marketed"},{"name":"Standard-dose rivaroxaban","genericName":"Standard-dose rivaroxaban","slug":"standard-dose-rivaroxaban","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Aspirin + Clopidogrel + Rivaroxaban","genericName":"Aspirin + Clopidogrel + Rivaroxaban","slug":"aspirin-clopidogrel-rivaroxaban","phase":"marketed","mechanism":"This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade.","indications":["Acute coronary syndrome with high thrombotic risk","Secondary prevention of cardiovascular events in post-acute coronary syndrome patients"],"catalyst":""},{"name":"Berberine plus lifestyle intervention","genericName":"Berberine plus lifestyle intervention","slug":"berberine-plus-lifestyle-intervention","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"De-escalated Dual Antiplatelet Therapy","genericName":"De-escalated Dual Antiplatelet Therapy","slug":"de-escalated-dual-antiplatelet-therapy","phase":"marketed","mechanism":"De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.","indications":["Acute coronary syndrome with percutaneous coronary intervention","Stable coronary artery disease with stent placement in high bleeding risk patients"],"catalyst":""},{"name":"Intensive BP treatment group","genericName":"Intensive BP treatment group","slug":"intensive-bp-treatment-group","phase":"phase_3","mechanism":"This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients.","indications":["Hypertension with cardiovascular disease or high cardiovascular risk"],"catalyst":""},{"name":"Oral anticoagulation therapy","genericName":"Oral anticoagulation therapy","slug":"oral-anticoagulation-therapy","phase":"marketed","mechanism":"Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.","indications":["Atrial fibrillation for stroke prevention","Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention","Mechanical heart valve thromboprophylaxis"],"catalyst":""},{"name":"Qishen Yiqi Drop Pills","genericName":"Qishen Yiqi Drop Pills","slug":"qishen-yiqi-drop-pills","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Single antiplatelet therapy","genericName":"Single antiplatelet therapy","slug":"single-antiplatelet-therapy","phase":"marketed","mechanism":"Single antiplatelet therapy inhibits platelet aggregation to reduce thrombotic events in cardiovascular disease.","indications":["Cardiovascular disease prevention","Acute coronary syndrome","Stroke prevention"],"catalyst":""},{"name":"Standard-dose rivaroxaban","genericName":"Standard-dose rivaroxaban","slug":"standard-dose-rivaroxaban","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Torsemide Tablets","genericName":"Torsemide Tablets","slug":"torsemide-tablets","phase":"marketed","mechanism":"Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.","indications":["Edema associated with congestive heart failure","Edema associated with renal disease","Hypertension"],"catalyst":""},{"name":"low-dose rivaroxaban","genericName":"low-dose rivaroxaban","slug":"low-dose-rivaroxaban","phase":"marketed","mechanism":"Low-dose rivaroxaban selectively inhibits Factor Xa in the coagulation cascade, reducing thrombin generation and blood clot formation at a lower dose than standard anticoagulation.","indications":["Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease","Stroke prevention in atrial fibrillation (at reduced doses)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPVWo0aUVodjRaU2FWQWNNdTU3WmlHeTBtbjJMOGp0S2pHRjh1UkRBMEJmSnRHUXFtdDhJQ2paSFo4Z002SzRXYkwwcDAtYjR6YUx1Z01ldVFYNFBWMnBMQVRTR2R5dDBfWFFnYk9vS3M2RWx1M2YteVVXQV93UnRZZmZWT2htM01SYjJwblNTM1hfNjVxaFlBeHYwUXdEOG12RGJ4OTFsLUVETE9C?oc=5","date":"2026-02-18","type":"pipeline","source":"Discover Magazine","summary":"This Ancient Practice May Lower Blood Pressure on Par With Some Drugs - Discover Magazine","headline":"This Ancient Practice May Lower Blood Pressure on Par With Some Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQM3VpRzd1M1VRWHdYQTNFUFAzWURLemstNFBtTmlJZkQ1b1NjNG02U2xsTnlQZEhycGpBM3ZydEU3NWxHanlnNlhHOEhXdmVDMWlyQ18xbDBmaVg4dnQzSTRmTjhOZ2NHd2gxRm9SaENGcElDN2pGcWhDdlZCYTZMaUc5ZnRhaWhYMk93ag?oc=5","date":"2026-02-02","type":"trial","source":"Market Data Forecast","summary":"Asia Pacific Pharmaceutical Market Size & Share, 2034 - Market Data Forecast","headline":"Asia Pacific Pharmaceutical Market Size & Share, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZjZFYkFTS1JrRkYyMUlnNnJUa3liYjVEZnV5QU5VcHBXUUw0ZTJNdXMxMVpmdjhnV2VaMTJRMzByRHBydmRsT09lNFY1M0p0RHg3ekZVaTd1WFJZMHBxWVc1LWYyWkF6RnB5T2dGQXZJSXI5TTBzLWJmUjNoaDVrdzI3WmtoWE40YXlkeVN4ZHlZTjFpTWlnWURDaEZ2VTF4VktRd0tFWHVWUQ?oc=5","date":"2025-12-13","type":"pipeline","source":"The Diplomat – Asia-Pacific Current Affairs Magazine","summary":"America’s Pharmaceutical Dependence on China Is a National Security Crisis - The Diplomat – Asia-Pacific Current Affairs Magazine","headline":"America’s Pharmaceutical Dependence on China Is a National Security Crisis - The Diplomat – Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNcEZJS2J3ZUJOV0ZTM3haNzMzbE1QakdSY1hHUEIyTTQtbk11bGVHb3c0WXlZWFhqSG5JNUdfZzlpRkpoemM1SDd1eS1feGFIY2VjTmg1UUY0VlB1SHlwZld2T2hpRlVCeWpuR1N5V1oxZWZNVERYenF2bEFENmZLYkNpV0dGZE5KZFFhcHhLMjdzZ3VVVGtkYUx4cGZrR2xIMkE?oc=5","date":"2025-07-09","type":"pipeline","source":"Frontiers","summary":"Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist’s role - Frontiers","headline":"Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxORkxBV2VtdDZUYV9Ta0M0MHJRRnlpVnBmbjVXYV9BZ01zN1hWQTN3WTZEb1JJcHVoWGlqWnNvd3ZOOWNQZjZaLXJ4Z2VZcHIwcEtUWEdZd1NaNlk2M0tGa21hbDZ1UnBmbE9jTHp2R1NrbUpUeGRsOFJLNHlscHRwMFZ6VE5RMzFiLTdJLU1kbFZGNXNKZmgzXzJzWks1UDM3Z1dqM2R1aEo1cEdY?oc=5","date":"2025-06-25","type":"deal","source":"Pharmaceutical Executive","summary":"Bayer Extends Partnership with Tsinghua University in China to Accelerate Drug Discovery - Pharmaceutical Executive","headline":"Bayer Extends Partnership with Tsinghua University in China to Accelerate Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HanBvS2JpRFYyOF9MSG5mNjdJVnloMVJCNWlxb3ZtczBrM1VrOENpRHdQZy1aWDJMeHM2X0tNWEpQbG9qZVlrYjkzaFRGYkdTa1lZbklabENnSVVaZ1NZ?oc=5","date":"2025-05-07","type":"trial","source":"nature.com","summary":"Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019 - nature.com","headline":"Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOdnlTNEh6YXNzQld1ek9QUUxNUF9aUXp0QjdxRm9ERmZZcEFUbDFQNjlqU1NPX0d4aDdmV1BGSHhfVDR3QWRETDFuNDBEWC0tajhIdG9IdzJNVUdrMnpIVVAzaFduZ1VlNHVHVmZKWkdKcGVabzlvckdYQUh2NzVIa19oaTFuTFR1TGZTS0dPM2lVRGVaS1VnWVV1UUFCSEVuMlI2QWxzOTF3Y0JuWURUM29qM0VBX3hpSTNqTVdvLUpYUThHYmtTTTVCNkhiUFBYUHJFQmhJWS1iT0ZnY3RRVA?oc=5","date":"2025-01-23","type":"pipeline","source":"Carnegie Endowment for International Peace","summary":"Biopharmaceuticals Rising: China’s Strategic Pivot to Southeast Asia Amid Great Power Tech Competition - Carnegie Endowment for International Peace","headline":"Biopharmaceuticals Rising: China’s Strategic Pivot to Southeast Asia Amid Great Power Tech Competition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBQek5uZXpoTWF6eGg5Tkh0MDZMSjhwRXk2aGkwSEJxVlY0REdxUl9oNlhxbk1VNUkwaktDLWpPRkZIOVRSa0Z1dXFkNjROYjB1UVlQdGNlTFp4TktxY3EzSmJtSXBfNlg5ZXM4?oc=5","date":"2024-06-27","type":"trial","source":"Wiley Online Library","summary":"Global trends in heart failure from 1990 to 2019: An age-period-cohort analysis from the Global Burden of Disease study - Wiley Online Library","headline":"Global trends in heart failure from 1990 to 2019: An age-period-cohort analysis from the Global Burden of Disease study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5VUXh6YmRZZG1ZU242QjVmMjk0RDlObWZNYWdRdElkMWItNjEzNlJlV0tzeUFLNkhRcnFtaDJJdjBJT2tXVG42NTJDTzRwT1RSRllXVGtHVG1kalRTT3FBUVBB?oc=5","date":"2023-06-27","type":"pipeline","source":"ACS Publications","summary":"Association of Long-Term Exposure to Ambient Fine Particulate Matter with Atherosclerotic Cardiovascular Disease Incidence Varies across Populations with Different Predicted Risks: The China-PAR Proje","headline":"Association of Long-Term Exposure to Ambient Fine Particulate Matter with Atherosclerotic Cardiovascular Disease Inciden","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQQVY1RmxaS0xYVUNjMFc1ZktBMnRkbkp3SXdZc0piLUxHd3ZDbU1VNl9uNGxRTWNZVkNCUDd3MWM0YzI3cUpnNjlCU2FRRnFvdnhZTTdMMU5OdkNBTFd1aWxiNXpXQkwtajl6TGRYM2tvOVdnOHpNaTBhODdGN3BiamxyV1RTUWlfbS12V05fVWF6RkVUOENZSjJHUWs5V19odjBBVGM3bEZZajllWVJBb29SSUk2MTl4NHNZ?oc=5","date":"2023-04-20","type":"pipeline","source":"Atlantic Council","summary":"The US is relying more on China for pharmaceuticals—and vice versa - Atlantic Council","headline":"The US is relying more on China for pharmaceuticals—and vice versa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbjlnQTZJVnhMamF5dGxSRjVsUG8tOGFoV1VQemUtd0FnelhLWkk1d0JkWVd3d0JoTndyTkZyYmdObnJZYTJqck1zcjBaZ2ZLZ1hfdU5Xdi15V1VxaDV4Y3RCalNGem9xc0NnQ21ZdEFWd2RRVzJSaElJYndxTVdTRFNrQmdJUFIzcFhZ?oc=5","date":"2022-12-14","type":"trial","source":"The Lancet","summary":"Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional s","headline":"Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBfTEhMWENlX3l5VlhTb2tYdGx6WDk1RTVrWGlQVm9QMG5BQjNFb1JjdllEaFBqOWpCQ0xRNDBQRGRGWFpWT2JmSTVNdGZyanFtSG9aR1d5UURPRncxSGtvdw?oc=5","date":"2021-02-24","type":"pipeline","source":"NEJM","summary":"Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality - NEJM","headline":"Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":9,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}